However, insufficient drug exposure was suggested to be one of the contributing factors to the development of resistance to RTK-targeted therapies in glioblastoma due to the heterogeneous expression of the epidermal growth factor receptor (EGFR) (Furnari et al., 2015). The gene discussed is EGFR; the disease is glioblastoma.